RxDoctor Payments Data

Prashanth Kumar, MD

Nephrology · Victorville, CANPI 1821293382

Payments from drug & device makers

$246,695in general payments, 2019–2025

Across 282 payments — averaging $874.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Quanta Dialysis Technologies Inc$229K
  • AstraZeneca$13K
  • Nxstage Medical, Inc.$2K
  • Outset Medical Inc$1K
  • Welch Allyn$206
  • Abbott$159
  • plus $770 from 14 others
$59,635in research payments, 2019–2025

Across 1 payment — averaging $59,635 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Quanta Dialysis Technologies Inc$60K

What the payments were for

  • Consulting fees$3,40017%
  • Speaking & faculty fees$14,17570%
  • Travel & lodging$680%
  • Food & beverage$2,05110%
  • Education$200%
  • Entertainment$1531%
  • Other$3272%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$246,695 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$136,461
Medicare patients
342
Services billed
1,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate44$29,846
AuryxiaFerric Citrate13$25,423
Lanthanum Carbonate13$9,709
Sevelamer Carbonate36$9,280
Calcium Acetate48$5,340
Nifedipine ErNifedipine38$1,089
Clonidine12$682
Gentamicin Sulfate15$431
Losartan Potassium48$217
Allopurinol29$205
Lisinopril38$201
Prednisone22$157
Furosemide28$157
Carvedilol41$135
Amlodipine Besylate40$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$13,421$29,84644 claims
Akebia Therapeutics IncAuryxia$24$25,42313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,341 nephrology providers in California.

Other nephrology in Victorville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →